Levy Adam D.
Chief Financial Officer
Levy Adam D. has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 6, 2026.
On the most recent filing, Levy Adam D. is listed as Chief Financial Officer at Acrivon Therapeutics, Inc. Inside the rolling window, Levy Adam D. reported 1 open-market purchase totaling $15K in ACRV and 1 open-market sale totaling $2K in ACRV. The largest disclosed transaction in the window is a purchase of 8,832 ACRV shares on Jan 14, 2026, worth $15K.
Companies traded
Other insiders at ACRV
Insider Buying
$15K
reported purchases (SEC code P)
Insider Selling
$2K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Levy Adam D. made?
Levy Adam D. has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Levy Adam D. trade?
Levy Adam D. has filed SEC Form 4 disclosures for 1 company, including ACRV.
When was Levy Adam D.'s most recent SEC Form 4 filing?
Levy Adam D.'s most recent SEC Form 4 filing on Tracefour is dated Aug 6, 2026.
What is Levy Adam D.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Levy Adam D. is listed as Chief Financial Officer.
What is Levy Adam D.'s total buy and sell value in the current window?
Inside the rolling retention window, Levy Adam D. bought $15K and sold $2K based on SEC Form 4 filings.
What was Levy Adam D.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 8,832 ACRV shares on 2026-01-14, worth $15K, per SEC Form 4 filings.